Risk Factors Update Summary
- Net loss decreased from $44 million in 2022 to $36 million in 2023.
- Accumulated deficit increased from $210 million to $246 million as of December 31, 2023.
- Revenue sources expanded to include sales of pipeline products and services, not just the PreTRM test.
- Losses may continue to increase as the company develops and commercializes new products.
- Federal NOL carryforwards increased from approximately $187 million to $211 million as of December 31, 2023.
- The company may be unable to generate sufficient revenue from sales of products and services to cover costs.
- The FDA proposed a rule to regulate Laboratory Developed Tests, potentially impacting the company's operations.
Full Text Changes in Most Recent 10-K
Intended use: review the highlighted statements. These are additions to the risk factors disclosure in the most recent 10-K filing compared to the previous 10-K filing. Deleted and moved text is less important and is shown for context.
To view the full company filings, click on the following link to be taken to the SEC EDGAR database landing page for the company: https://www.sec.gov/edgar/browse/?CIK=1534969&owner=exclude
This content requires a 'Free' membership to view. Please create one here.
This content requires a 'Free' membership to view. Please create one here.